Mostrar el registro sencillo del ítem

dc.contributor.authorSalazar de Pablo, Gonzalo
dc.contributor.authorJiménez Fernández, Sara
dc.date.accessioned2021-02-01T12:10:22Z
dc.date.available2021-02-01T12:10:22Z
dc.date.issued2020
dc.identifier.citationSalazar de Pablo G, Guinart D, Cornblatt BA, Auther AM, Carrión RE, Carbon M, Jiménez-Fernández S, Vernal DL, Walitza S, Gerstenberg M, Saba R, Lo Cascio N, Brandizzi M, Arango C, Moreno C, Van Meter A, Fusar-Poli P and Correll CU (2020) DSM-5 Attenuated Psychosis Syndrome in Adolescents Hospitalized With Non-psychotic Psychiatric Disorders. Front. Psychiatry 11:568982. doi: 10.3389/fpsyt.2020.568982es_ES
dc.identifier.urihttp://hdl.handle.net/10481/66175
dc.description.abstractIntroduction: Although attenuated psychotic symptoms often occur for the first time during adolescence, studies focusing on adolescents are scarce. Attenuated psychotic symptoms form the criteria to identify individuals at increased clinical risk of developing psychosis. The study of individuals with these symptoms has led to the release of the DSM-5 diagnosis of Attenuated Psychosis Syndrome (APS) as a condition for further research. We aimed to characterize and compare hospitalized adolescents with DSM-5-APS diagnosis vs. hospitalized adolescents without a DSM-5-APS diagnosis. Methods: Interviewing help-seeking, hospitalized adolescents (aged 12–18 years) and their caregivers independently with established research instruments, we (1) evaluated the presence of APS among non-psychotic adolescents, (2) characterized and compared APS and non-APS individuals regarding sociodemographic, illness and intervention characteristics, (3) correlated psychopathology with levels of functioning and severity of illness and (4) investigated the influence of individual clinical, functional and comorbidity variables on the likelihood of participants to be diagnosed with APS. Results: Among 248 consecutively recruited adolescents (age=15.4 ± 1.5 years, females = 69.6%) with non-psychotic psychiatric disorders, 65 (26.2%) fulfilled APS criteria and 183 (73.8%) did not fulfill them. Adolescents with APS had higher number of psychiatric disorders than non-APS adolescents (3.5 vs. 2.4, p < 0.001; Cohen’s d = 0.77), particularly, disruptive behavior disorders (Cramer’s V = 0.16), personality disorder traits (Cramer’s V = 0.26), anxiety disorders (Cramer’s V = 0.15), and eating disorders (Cramer’s V = 0.16). Adolescents with APS scored higher on positive (Cohen’s d = 1.5), negative (Cohen’s d = 0.55), disorganized (Cohen’s d = 0.51), and general symptoms (Cohen’s d = 0.84), and were more severely ill (Cohen’s d = 1.0) and functionally impaired (Cohen’s d = 0.31). Negative symptoms were associated with lower functional levels (Pearson ρ = −0.17 to −0.20; p = 0.014 to 0.031). Global illness severity was associated with higher positive, negative, and general symptoms (Pearson ρ = 0.22 to 0.46; p = 0.04 to p < 0.001). APS status was independently associated with perceptual abnormalities (OR = 2.0; 95% CI = 1.6–2.5, p < 0.001), number of psychiatric diagnoses (OR = 1.5; 95% CI = 1.2–2.0, p = 0.002), and impaired stress tolerance (OR = 1.4; 95% CI = 1.1–1.7, p = 0.002) (r 2 = 0.315, p < 0.001). Conclusions: A considerable number of adolescents hospitalized with non-psychotic psychiatric disorders meet DSM-5-APS criteria. These help-seeking adolescents have more comorbid disorders and more severe symptoms, functional impairment, and severity of illness than non-APS adolescents. Thus, they warrant high intensity clinical care.es_ES
dc.description.sponsorshipJohn and Maxine Bendheim Foundationes_ES
dc.description.sponsorshipAlicia Koplowitz Foundationes_ES
dc.description.sponsorshipSpanish Governmentes_ES
dc.description.sponsorshipERDF Funds from the European Commission, A way of making Europe, CIBERSAM PI17/02227es_ES
dc.description.sponsorshipMadrid Regional Government B2017/BMD-3740 AGES-CM-2es_ES
dc.description.sponsorshipEuropean Union (EU) FP7-4-HEALTH-2009-2.2.1-2-241909 FP7-HEALTH-2013-2.2.1-2-603196 FP7-HEALTH-2013-2.2.1-2-602478es_ES
dc.description.sponsorshipEuropean Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking 115916 777394es_ES
dc.description.sponsorshipFundacion Familia Alonsoes_ES
dc.description.sponsorshipInstituto de Salud Carlos IIIes_ES
dc.language.isoenges_ES
dc.publisherFRONTIERS MEDIA SAes_ES
dc.rightsAtribución 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectAttenuated Psychosis Syndrome (APS)es_ES
dc.subjectAdolescencees_ES
dc.subjectEpidemiology es_ES
dc.subjectRiskes_ES
dc.subjectPsychosises_ES
dc.subjectPrevention es_ES
dc.titleDSM-5 Attenuated Psychosis Syndrome in Adolescents Hospitalized With Non-psychotic Psychiatric Disorderses_ES
dc.typejournal articlees_ES
dc.relation.projectIDeu-repo/grantAgreement/EC/H2020/115916 777394es_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.3389/fpsyt.2020.568982


Ficheros en el ítem

[PDF]

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 3.0 España
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 3.0 España